Merck (NYSE:MRK) received a positive opinion from the EMA’s CHMP for KEYTRUDA plus Padcev in muscle-invasive bladder cancer. The CHMP backed the combination as perioperative therapy for adults with ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive ...

Merck & Co., Inc. MRK secured a favorable recommendation from a European regulatory committee for its cancer therapy Keytruda in combination with Padcev to treat adults facing resectable ...

Interim analysis shows goals were met for recurrence and preventing cancer spread Moderna spikes as much as 160%; Merck jumps 12% Barclays estimates therapy could reach about $3 billion in melanoma ...

If approved, KEYTRUDA plus Padcev would become the first and only PD-1 inhibitor plus antibody-drug conjugate regimen for patients with MIBC regardless of cisplatin eligibility in the European Union.

Drug major Merck & Co., Inc. ( MRK) announced Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending approval of ...

Inhibrx Biosciences (INBX) stock gains as cancer therapy INBRX-106 with Merck (MRK) Keytruda outperforms the blockbuster drug ...

Drugmaker Merck is testing its antibody-drug conjugates (ADCs) alone and with its signature immunotherapy drug Keytruda ...

Summit Therapeutics (SMMT) on Sunday said ivonescimab significantly extended survival compared with Merck’s (MRK) Keytruda in ...

Interim data from a large trial showed the experimental vaccine, when combined with Merck's blockbuster immunotherapy Keytruda, helped reduce the risk of melanoma recurrence and spread in ‌patients ...

Inhibrx CEO Mark Lappe was particularly keen on INBRX-106’s performance in patients with HPV-positive disease and sees a ...

Merck receives positive EU CHMP opinion for Keytruda plus Padcev as perioperative treatment for adults with resectable MIBC: Rahway, New Jersey Saturday, September 19, 2026, 11:00 ...